Navigation Links
Clemson bioengineer uses nanoparticles to target drugs
Date:10/8/2009

f their physical and chemical properties."

A handful of nanoparticle medicines already have been approved for use treating diseases, particularly cancers. Alexis and other bioengineers are ushering in a new era in medicine.

A challenge for oral medicines, for example, is getting them to do some good before the body destroys them. A patient's metabolism can do its job too well taking a drug out of circulation.

Called "first-pass metabolism," the liver breaks down a drug during its first trip circulating through the body. The result is doctors must use greater amounts of oral medicines to achieve the therapeutic effect. Negative reactions from the higher doses or the inconvenience from prolonged treatment cause many patients to stop taking their medicines.

Nanoparticles can be made to survive the first pass. The particles also can be made to get beyond the body's immune system. Multi-layers on the nanoparticles or nanoshells can resist the body's defenses, enabling the medicine to last longer or reach the intended location.

Dendrimers are nanoparticles that could become the Swiss Army knives of targeted drug delivery. The particles can be made so that a number of different kinds of molecules could be attached to it. One group of molecules could fight the disease, another could enhance images to track the drug, a third could carry a chemical trigger to release the medicine by command from outside the body, another, still, that could send signals about results.

"We are moving ahead in nanoscience in laboratories throughout the world," said Alexis. "Nanoparticle functionalities become more and more complex and the next step is for the research to develop technologies allowing their transfer from the research bench to a pharmaceutical drug. New ways of targeting drugs that will be more effective and safe and more agreeable to patients is just over the horizon."


'/>"/>

Contact: Peter Kent
pkent@clemson.edu
864-656-4355
Clemson University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clemson researchers study energy savings with electric cars and IntelliDrive technology
2. Clemson research nets $2 million from NSF to mimic natures probes
3. Clemson and collaborators receive $1.1 million to improve durability of concrete infrastructure
4. Clemson chemists present revolutionary teaching concepts
5. Clemson physicist Apparao Rao named Fellow of the American Physical Society
6. Clemson researchers advance nano-scale electromechanical sensors
7. US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board
8. National Science Foundation grants Clemson professors award to develop nanoprobes
9. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
10. Clemson bioengineer wins prestigious Early Career Award
11. NIH recognizes Clemson nanotechnology for molecule tracking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... potential for an outbreak of the phenomenon commonly called ... spring and summer, according to researchers with the Woods ... (NCSU). This advisory is based in part ... Alexandrium fundyense the algae notorious ...
... international team of researchers from China and the United ... Early Cretaceous rocks in the southern part of the ... Jiayuguan, Gansu Province, China. Two of their discoveries represent ... in technical publications published on-line in the Proceedings ...
... in French . Scientists at the ... Japan along with researchers from McGill University and other ... are controlled in mammals. Three years of intensive research by ... publication of several milestone scientific papers in Nature Genetics ...
Cached Biology News:Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 2Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 3Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 4Field Museum paleontologist leads study on two new dinosaurs from China 2Field Museum paleontologist leads study on two new dinosaurs from China 3Field Museum paleontologist leads study on two new dinosaurs from China 4Major international study challenges notions of how genes are controlled in mammals 2
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/27/2015)... Francisco, CA (PRWEB) February 27, 2015 ... joining forces on February 28 with patients and health ... raise awareness for Rare Disease Day®. Rare Disease ... diseases and calling attention to the special challenges faced ... around them. , “Cytokinetics is proud to stand alongside ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... Therapeutics Inc. (TSX:,LOR, AMEX: LRP) ("Lorus" or ... research and development of pharmaceutical products and,technologies ... progress made in,the Virulizin(R) development program, including ... Virulizin(R) mode of action and the issuance ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... Vice President, Global Supply Chain and,Sustainment Engineering. He ... of Alexza,s global supply chain strategy to,support the ... lead program, AZ-004 (Staccato(R) loxapine) is in,Phase 3 ...
... ... Advisory Board --, SAN DIEGO, July 9 ... has received regulatory approval to,begin a Phase 2a proof-of-concept clinical trial ... arthritis, is a,painful and debilitating disease caused by abnormally elevated levels ...
Cached Biology Technology:Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 4
... early protein. Can detect ... exhibiting an intranuclear inclusion staining ... 6-24 hours. These antibodies ... staining. No other nuclear ...
MAb to Vasopressin Preservative: NaN3...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: